Cereno Scientific announces resignation of Chairperson of the Board at his own request
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that Jeppe Øvlesen has informed the Board of Directors of his decision to resign as Chairperson and member of the Board at his own request, effective immediately.
“I have greatly valued my time as Chairperson of the Board of Cereno Scientific and the opportunity to work alongside Sten, his team and my fellow Board members. As the demands and responsibilities of the Chairperson role have increased, I have come to the conclusion that I am no longer best placed to fulfil the requirements of the position. I have therefore decided to step down. This decision does not change my confidence in the company’s science and the potential of its drug development programs. I wish Cereno and its team every success going forward,” said Jeppe Øvlesen.
“We respect Jeppe’s decision and thank him for his contributions and commitment during his time on the Board. We wish him every success in his future endeavors. Our focus remains on advancing Cereno’s drug development programs and executing our financing plans to support the company’s continued development,” said Sten R. Sörensen, CEO of Cereno Scientific.
According to Cereno Scientific’s Articles of Association, the Board of Directors shall consist of a minimum of four and a maximum of eight members. Following Jeppe Øvlesen’s resignation, the Board will consist of four members and will therefore continue to comply with the requirements of the Articles of Association. The Board will announce its designated Chairperson as soon as possible.